GlassScriptPhysician profile
Susan D Decoste
NPI 1942284591
$17,767.89
in general payments reported to CMS, 2019-2025
35 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $1,789 · 2021: $2,484 · 2022: $2,701 · 2023: $2,974 · 2024: $2,836 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,455 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,454.65 |
| Education | $203.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,189.73 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Leo Pharma INC. | $1,835.22 | 2019-2025 | Adbry, Anzupgo |
| Merz North America, INC. | $1,143.46 | 2019-2024 | Xeomin |
| Genzyme Corporation | $1,079.39 | 2019-2025 | |
| Incyte Corporation | $991.31 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $956.18 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $932.94 | 2019-2025 | |
| Allergan, INC. | $912.48 | 2019-2022 | |
| Revance Therapeutics, INC. | $772.85 | 2024-2025 | Daxxify, Daxi |
| E.R. Squibb & Sons, L.L.C. | $744.10 | 2022-2025 | Sotyktu |
| Amgen INC. | $734.93 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $691.37 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $549.65 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $456.92 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $413.62 | 2019-2025 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Decoste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.